List view / Grid view
Study highlights benefit of initiating high-efficacy therapies early for relapsing…
Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.
Sanofi and its subsidiary Genzyme announced that the European Commission…
30 August 2013 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)...
Sanofi and Genzyme announced that key data from the TOWER…
12 October 2012 | By Sanofi
Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS...
Swissmedic and TGA have granted approval for Gilenya® (fingolimod)...
24 January 2011 | By Novartis
Swissmedic and TGA have granted approval for Gilenya® (fingolimod)...
